In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist

Jeffrey M. Witkin, Paul L. Ornstein, Charles H. Mitch, Renhua Li, Stephon C. Smith, Beverly A. Heinz, Xu Shan Wang, Chuanxi Xiang, Joan H. Carter, Wesley H. Anderson, Xia Li, Lisa M. Broad, Francesca Pasqui, Stephen M. Fitzjohn, Helen E. Sanger, Jodi Smith, John Catlow, Steven Swanson, James A. Monn

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Metabotropic glutamate 2/3 (mGlu2/3) receptors are of considerable interest owing to their role in modulating glutamate transmission via presynaptic, postsynaptic and glial mechanisms. As part of our ongoing efforts to identify novel ligands for these receptors, we have discovered (1S,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid; (LY3020371), a potent and selective orthosteric mGlu2/3 receptor antagonist. In this account, we characterize the effects of LY3020371 in membranes and cells expressing human recombinant mGlu receptor subtypes as well as in native rodent and human brain tissue preparations, providing important translational information for this molecule. In membranes from cells expressing recombinant human mGlu2 and mGlu3 receptor subtypes, LY3020371.HCl competitively displaced binding of the mGlu2/3 agonist ligand [3H]-459477 with high affinity (hmGlu2 Ki = 5.26 nM; hmGlu3 Ki = 2.50 nM). In cells expressing hmGlu2 receptors, LY3020371.HCl potently blocked mGlu2/3 agonist (DCG-IV)-inhibited, forskolin-stimulated cAMP formation (IC50 = 16.2 nM), an effect that was similarly observed in hmGlu3-expressing cells (IC50 = 6.21 nM). Evaluation of LY3020371 in cells expressing the other human mGlu receptor subtypes revealed high mGlu2/3 receptor selectivity. In rat native tissue assays, LY3020371 demonstrated effective displacement of [3H]-459477 from frontal cortical membranes (Ki = 33 nM), and functional antagonist activity in cortical synaptosomes measuring both the reversal of agonist-suppressed second messenger production (IC50 = 29 nM) and agonist-inhibited, K+-evoked glutamate release (IC50 = 86 nM). Antagonism was fully recapitulated in both primary cultured cortical neurons where LY3020371 blocked agonist-suppressed spontaneous Ca2+ oscillations (IC50 = 34 nM) and in an intact hippocampal slice preparation (IC50 = 46 nM). Functional antagonist activity was similarly demonstrated in synaptosomes prepared from epileptic human cortical or hippocampal tissues, suggesting a translation of the mGlu2/3 antagonist pharmacology from rat to human. Intravenous dosing of LY3020371 in rats led to cerebrospinal fluid drug levels that are expected to effectively block mGlu2/3 receptors in vivo. Taken together, these results establish LY3020371 as an important new pharmacological tool for studying mGlu2/3 receptors in vitro and in vivo.

Original languageEnglish (US)
JournalNeuropharmacology
DOIs
StateAccepted/In press - Oct 5 2015

Keywords

  • LY3020371
  • Metabotropic glutamate receptors
  • MGlu
  • MGlu

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Fingerprint Dive into the research topics of 'In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu<sub>2/3</sub> receptor antagonist'. Together they form a unique fingerprint.

  • Cite this

    Witkin, J. M., Ornstein, P. L., Mitch, C. H., Li, R., Smith, S. C., Heinz, B. A., Wang, X. S., Xiang, C., Carter, J. H., Anderson, W. H., Li, X., Broad, L. M., Pasqui, F., Fitzjohn, S. M., Sanger, H. E., Smith, J., Catlow, J., Swanson, S., & Monn, J. A. (Accepted/In press). In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2015.12.021